Digestive and Liver Disease最新文献

筛选
英文 中文
Clinical characteristics and risk factors of hepatocellular carcinoma development in Budd-Chiari syndrome patients after endovascular treatment 布-恰利综合征血管内治疗后肝癌发生的临床特点及危险因素分析。
IF 4 3区 医学
Digestive and Liver Disease Pub Date : 2025-06-01 DOI: 10.1016/j.dld.2025.02.008
Qianxin Huang , Qingqiao Zhang , Hao Xu , Maoheng Zu , Yuming Gu , He Ma , Wei Kang , Caifang Ni
{"title":"Clinical characteristics and risk factors of hepatocellular carcinoma development in Budd-Chiari syndrome patients after endovascular treatment","authors":"Qianxin Huang ,&nbsp;Qingqiao Zhang ,&nbsp;Hao Xu ,&nbsp;Maoheng Zu ,&nbsp;Yuming Gu ,&nbsp;He Ma ,&nbsp;Wei Kang ,&nbsp;Caifang Ni","doi":"10.1016/j.dld.2025.02.008","DOIUrl":"10.1016/j.dld.2025.02.008","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Endovascular treatment has improved Budd-Chiari syndrome (BCS) patient outcomes, but patients remain at risk for developing hepatocellular carcinoma (HCC). We aimed to analyse the characteristics and risk factors for HCC development in BCS patients after endovascular treatment.</div></div><div><h3>Methods</h3><div>Clinical data of BCS patients who had received endovascular treatment were retrospectively reviewed. Characteristics of BCS patients who developed HCC post-treatment were compared with those without HCC development. Univariable and multivariable Cox regression analyses were used to determine the risk factors.</div></div><div><h3>Results</h3><div>We enrolled 302 BCS patients. HCC was confirmed in 31 patients after treatment. Early-stage tumours were the most common (11/31, 35.5 %) according to the Barcelona Clinic Liver Cancer staging system. A serum alpha fetoprotein (AFP) cut-off level of &gt; 15.7 ng/mL showed a sensitivity of 69.3 % and specificity of 97.4 % for detecting HCC in these patients. The presence of preoperative liver cirrhosis (hazard ratio (HR)=4.677; <em>P</em> = 0.043) and postoperative restenosis (HR=6.867; <em>P</em> &lt; 0.001) were independent risk factors associated with HCC development in BCS patients after endovascular treatment.</div></div><div><h3>Conclusion</h3><div>HCCs that develop after endovascular treatment in BCS patients are often detected at an early stage. Preoperative liver cirrhosis and postoperative restenosis were independent risk factors for HCC development in these individuals.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1301-1307"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of bacterial infection on the risk of portal vein thrombosis development in patients with cirrhosis: A post-hoc analysis 细菌感染对肝硬化患者门静脉血栓形成风险的影响:事后分析。
IF 4 3区 医学
Digestive and Liver Disease Pub Date : 2025-06-01 DOI: 10.1016/j.dld.2025.03.024
Simone Di Cola , Jakub Gazda , Stefano Fonte , Lucia Lapenna , Silvia Nardelli , Giulia Cusi , Adriano De Santis , Manuela Merli
{"title":"The impact of bacterial infection on the risk of portal vein thrombosis development in patients with cirrhosis: A post-hoc analysis","authors":"Simone Di Cola ,&nbsp;Jakub Gazda ,&nbsp;Stefano Fonte ,&nbsp;Lucia Lapenna ,&nbsp;Silvia Nardelli ,&nbsp;Giulia Cusi ,&nbsp;Adriano De Santis ,&nbsp;Manuela Merli","doi":"10.1016/j.dld.2025.03.024","DOIUrl":"10.1016/j.dld.2025.03.024","url":null,"abstract":"<div><h3>Background</h3><div>Portal vein thrombosis (PVT) is a common complication in liver cirrhosis. Bacterial infections (BIs) may increase PVT risk through bacterial translocation, systemic inflammation, and coagulation dysfunction, but evidence is limited.</div></div><div><h3>Aims</h3><div>This study investigates the 6-month risk of onset of PVT in patients hospitalized with BIs.</div></div><div><h3>Methods</h3><div>This post-hoc analysis included 563 cirrhotic patients hospitalized between 2011 and 2021, with or without BIs diagnosis, and followed for 6 months post-discharge. Patients with HCC outside of Milan criteria were excluded. The main endpoint was the onset of PVT, diagnosed via abdominal ultrasound or CT/MRI.</div></div><div><h3>Results</h3><div>BI was diagnosed in 146 patients (26 %). Forty-seven patients (8.5 %) experienced PVT events within 6 months, including 15 (10 %) with BIs and 32 (7.8 %) without (<em>p</em> = 0.4). Logistic regression showed no significant effect of BI on PVT occurrence (OR 1.35, 95 % CI 0.69–2.54), even after adjusting for confounding factors. However, urinary tract infections were independently associated with higher PVT risk (OR 3.17, 95 % CI 1.05–10.8, <em>p</em> = 0.048). Other infection sites (pneumonia, spontaneous bacterial peritonitis-SBP, spontaneous bacteremia) and isolated microbial strains (<em>n</em> = 77) were not associated with increased PVT risk. When analyzing the population excluding patients with HCC, the risk of developing PVT was significantly higher in patients with previous BI, regardless of the severity of liver disease (OR 2.92, 95 % CI 1.06–8.16).</div></div><div><h3>Conclusions</h3><div>In this large cohort, BIs did not significantly increase PVT risk within 6 months post-hospitalization in cirrhotic patients. However, when the cohort was reduced to patients without HCC, the risk of PVT appears to be significant.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1260-1265"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and staging of chronic pancreatitis-Diagnostic accuracy and agreement between endoscopic ultrasound and transabdominal ultrasound shear wave elastography 慢性胰腺炎的诊断和分期——内镜超声和经腹超声剪切波弹性成像诊断的准确性和一致性。
IF 4 3区 医学
Digestive and Liver Disease Pub Date : 2025-06-01 DOI: 10.1016/j.dld.2025.03.013
Carlo Felix Maria Jung , Cecilia Binda , Elisa Liverani , Elton Dajti , Carmela Abbatiello , Ludovica Cristofaro , Luigina Vanessa Alemanni , Alessandro Sartini , Barbara Perini , Paolo Giuffrida , Chiara Coluccio , Giulia Gibiino , Stefano Fabbri , Carla Serra , Carlo Fabbri
{"title":"Diagnosis and staging of chronic pancreatitis-Diagnostic accuracy and agreement between endoscopic ultrasound and transabdominal ultrasound shear wave elastography","authors":"Carlo Felix Maria Jung ,&nbsp;Cecilia Binda ,&nbsp;Elisa Liverani ,&nbsp;Elton Dajti ,&nbsp;Carmela Abbatiello ,&nbsp;Ludovica Cristofaro ,&nbsp;Luigina Vanessa Alemanni ,&nbsp;Alessandro Sartini ,&nbsp;Barbara Perini ,&nbsp;Paolo Giuffrida ,&nbsp;Chiara Coluccio ,&nbsp;Giulia Gibiino ,&nbsp;Stefano Fabbri ,&nbsp;Carla Serra ,&nbsp;Carlo Fabbri","doi":"10.1016/j.dld.2025.03.013","DOIUrl":"10.1016/j.dld.2025.03.013","url":null,"abstract":"<div><h3>Background</h3><div>Diagnosis of chronic pancreatitis (CP) is invasive and depending on endoscopic ultrasound (EUS) evaluation using Rosemont Criteria (RC). Non invasive ultrasound (US) based tests are necessary to detect CP.</div></div><div><h3>Aim</h3><div>We compared transabdominal 2D Shear Wave Elastography (SWE) of the pancreas and the Gemelli Ultrasound Chronic Pancreatitis Score to EUS/RC for the diagnosis of chronic pancreatitis.</div></div><div><h3>Methods</h3><div>We conducted a single center prospective case-control study. EUS with RC defined cohorts with (<em>n</em> = 51) and without CP (<em>n</em> = 51). Patients underwent US evaluation of the pancreas using 2D SWE and USCP.</div></div><div><h3>Results</h3><div>Median SWE values were different between groups (no CP 1.45m/s; IQR 1.34–1.60 and with CP 1.72m/s; IQR 1.63–1.96; <em>p</em> &lt; 0.0001) and different between RC subgroups (RC indeterminate for CP 1.67m/s, IQR 1.52–1.72 vs. RC suggestive 1.72m/s, IQR 1.62–1.97 vs. RC consistent with CP 1.90 m/s, IQR 1.72–2.12 m/s; <em>p</em> &lt; 0.0001). Median USCP was different between groups. 2D SWE correlated with USCP (<em>p</em> &lt; 0.0001) and RC (<em>p</em> &lt; 0.0001). We defined a cut off SWE value of &lt;1.42m/s to rule out CP (Sensitivity 96 %; NPV 92 %) and a SWE cut off &gt;1.87m/s to diagnose CP (Specifity 96 %;PPV 90 %).</div></div><div><h3>Conclusion</h3><div>Pancreatic US evaluation with 2D SWE is a widely applicable and unexpensive tool for the diagnosis of CP. Larger studies are needed to confirm these results.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1280-1287"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author's reply: “Aetiology-specific inflammation patterns in patients and rat models of compensated cirrhosis: New perspectives and recommendations” 作者回复:“代偿性肝硬化患者和大鼠模型的病因特异性炎症模式:新的观点和建议”。
IF 4 3区 医学
Digestive and Liver Disease Pub Date : 2025-06-01 DOI: 10.1016/j.dld.2025.04.022
Benedikt Silvester Hofer , Thomas Reiberger
{"title":"Author's reply: “Aetiology-specific inflammation patterns in patients and rat models of compensated cirrhosis: New perspectives and recommendations”","authors":"Benedikt Silvester Hofer ,&nbsp;Thomas Reiberger","doi":"10.1016/j.dld.2025.04.022","DOIUrl":"10.1016/j.dld.2025.04.022","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1350-1351"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The significance of the modified surgical apgar score in predicting postoperative acute kidney injury among patients undergoing hepatectomy 改良手术apgar评分预测肝切除术患者术后急性肾损伤的意义。
IF 4 3区 医学
Digestive and Liver Disease Pub Date : 2025-06-01 DOI: 10.1016/j.dld.2025.01.207
Jiayu Feng , Rongdang Fu , Lei Zhang , Dong Yang , Hanbing Wang
{"title":"The significance of the modified surgical apgar score in predicting postoperative acute kidney injury among patients undergoing hepatectomy","authors":"Jiayu Feng ,&nbsp;Rongdang Fu ,&nbsp;Lei Zhang ,&nbsp;Dong Yang ,&nbsp;Hanbing Wang","doi":"10.1016/j.dld.2025.01.207","DOIUrl":"10.1016/j.dld.2025.01.207","url":null,"abstract":"<div><h3>Aim</h3><div>The incidence of acute kidney injury (AKI) following hepatectomy ranges from 0.9 % to 21.6 %. Postoperative AKI is associated with increased mortality, prolonged hospital stays, and more healthcare costs. Previous predictive models either neglected intraoperative factors or were excessively complicated for application. Based on estimated blood loss, minimum heart rate, and minimum mean arterial pressure, the Surgical Apgar Score (SAS) has been validated as an indicator of major complications and outcomes following surgeries. Furthermore, previous studies have linked hematocrit levels to the incidence of AKI. Our aim was to determine whether the modified SAS, calculated using both SAS and hematocrit, could accurately predict AKI following hepatectomy.</div></div><div><h3>Methods</h3><div>This retrospective study ultimately enrolled 960 patients who underwent hepatectomy. The study included a total of 28 preoperative and intraoperative variables. Univariate and multivariate logistic regression analyses were performed to determine the predictive ability of the modified SAS.</div></div><div><h3>Results</h3><div>We demonstrated significant associations between the modified SAS and the incidence of AKI (OR 0.65, 95 % CI 0.54–0.78, <em>p</em> &lt; 0.001). A lower total score increases the likelihood of postoperative AKI, with a cutoff value set at 9.</div></div><div><h3>Conclusions</h3><div>The modified SAS appears to be a valid predictive factor for AKI following hepatectomy.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1288-1293"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI-based measurement of adipose body composition in patients with acute pancreatitis: The holy grail to define the prognosis? 基于人工智能的急性胰腺炎患者脂肪体组成测量:确定预后的圣杯?
IF 4 3区 医学
Digestive and Liver Disease Pub Date : 2025-06-01 DOI: 10.1016/j.dld.2025.02.012
Antonio Facciorusso , Enrique De-Madaria
{"title":"AI-based measurement of adipose body composition in patients with acute pancreatitis: The holy grail to define the prognosis?","authors":"Antonio Facciorusso ,&nbsp;Enrique De-Madaria","doi":"10.1016/j.dld.2025.02.012","DOIUrl":"10.1016/j.dld.2025.02.012","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1216-1217"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author's reply: “Refining Superb microvascular imaging for Crohn’s disease: Key considerations and future directions” 作者回复:“改进克罗恩病的微血管成像:关键考虑和未来方向”。
IF 4 3区 医学
Digestive and Liver Disease Pub Date : 2025-06-01 DOI: 10.1016/j.dld.2025.05.002
Sophie Haberkamp, Sebastian Zundler
{"title":"Author's reply: “Refining Superb microvascular imaging for Crohn’s disease: Key considerations and future directions”","authors":"Sophie Haberkamp,&nbsp;Sebastian Zundler","doi":"10.1016/j.dld.2025.05.002","DOIUrl":"10.1016/j.dld.2025.05.002","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 7","pages":"Page 1534"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author's Reply: “Ustekinumab and vedolizumab: A step forward in managing complex perianal fistulas in Crohn's disease” 作者回复:“Ustekinumab和vedolizumab:治疗克罗恩病复杂肛周瘘的新进展”。
IF 4 3区 医学
Digestive and Liver Disease Pub Date : 2025-06-01 DOI: 10.1016/j.dld.2025.04.005
María José Casanova, María Chaparro, Javier P. Gisbert
{"title":"Author's Reply: “Ustekinumab and vedolizumab: A step forward in managing complex perianal fistulas in Crohn's disease”","authors":"María José Casanova,&nbsp;María Chaparro,&nbsp;Javier P. Gisbert","doi":"10.1016/j.dld.2025.04.005","DOIUrl":"10.1016/j.dld.2025.04.005","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1340-1341"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global burden of gallbladder cancer in 2022 and predictions to 2042 2022年全球胆囊癌负担及到2042年的预测。
IF 4 3区 医学
Digestive and Liver Disease Pub Date : 2025-06-01 DOI: 10.1016/j.dld.2025.02.007
Hanfeng Guo , Decai Zhang , Zhaoqi Li , Shaojun Liu , Rui Wang
{"title":"Global burden of gallbladder cancer in 2022 and predictions to 2042","authors":"Hanfeng Guo ,&nbsp;Decai Zhang ,&nbsp;Zhaoqi Li ,&nbsp;Shaojun Liu ,&nbsp;Rui Wang","doi":"10.1016/j.dld.2025.02.007","DOIUrl":"10.1016/j.dld.2025.02.007","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>This study aims to provide updated estimate on the global burden of Gallbladder cancer (GBC) in 2022 and to predict the trends through the year 2042.</div></div><div><h3>Methods</h3><div>Data were extracted from GLOBOCAN 2022 database. Incidence and mortality rates were calculated by sex, country, world region and Human Development Index (HDI). Trends up to the year 2042 were predicted based on global demographic projections by HDI.</div></div><div><h3>Results</h3><div>Worldwide, there were 122,469 new GBC cases and 89,045 deaths identified in 2022. While the highest absolute number was observed in South Central Asia and Eastern Asia, particularly India and China, countries in South America, particularly Bolivia, showed the highest age-standardised rate. Medium HDI countries showed more than double the incidence and mortality rates compared to low HDI countries. Over half of GBC cases and deaths occurred in individuals aged 50–74 years. Predictions indicate a 65.3 % increase in new cases and a 67.6 % increase in deaths by 2042, with High HDI countries and Low HDI countries experiencing the largest absolute and percentage increases, respectively.</div></div><div><h3>Conclusions</h3><div>The global burden of GBC is substantial, especially concentrated in South Central Asia, Eastern Asia and South America. With significant increase of burden over the next 20 years, there is an urgent need for effective cancer control strategies in regions exhibiting great GBC burden.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Pages 1294-1300"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on “Intrahepatic cholangiocarcinoma with FGFR alterations: A series of Chinese cases with an emphasis on their clinicopathologic and genetic features” 《肝内胆管癌伴FGFR改变:一系列中国病例的临床病理和遗传学特征》评论
IF 4 3区 医学
Digestive and Liver Disease Pub Date : 2025-06-01 DOI: 10.1016/j.dld.2025.02.023
Preeti Advani, Santosh Kumar
{"title":"Comment on “Intrahepatic cholangiocarcinoma with FGFR alterations: A series of Chinese cases with an emphasis on their clinicopathologic and genetic features”","authors":"Preeti Advani,&nbsp;Santosh Kumar","doi":"10.1016/j.dld.2025.02.023","DOIUrl":"10.1016/j.dld.2025.02.023","url":null,"abstract":"<div><div>&lt;Dummy abstract&gt;</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 6","pages":"Page 1354"},"PeriodicalIF":4.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信